WO1999063086A3 - Variantes de la proteine-3 de liaison du facteur de croissance de type insulinoide - Google Patents

Variantes de la proteine-3 de liaison du facteur de croissance de type insulinoide Download PDF

Info

Publication number
WO1999063086A3
WO1999063086A3 PCT/US1999/012087 US9912087W WO9963086A3 WO 1999063086 A3 WO1999063086 A3 WO 1999063086A3 US 9912087 W US9912087 W US 9912087W WO 9963086 A3 WO9963086 A3 WO 9963086A3
Authority
WO
WIPO (PCT)
Prior art keywords
igfbp
variants
disclosed
growth factor
insulin
Prior art date
Application number
PCT/US1999/012087
Other languages
English (en)
Other versions
WO1999063086A2 (fr
WO1999063086B1 (fr
WO1999063086A8 (fr
Inventor
Desmond Mascarenhas
Stephen Danko
David Passmore
Original Assignee
Celtrix Pharmacueticals Inc
Desmond Mascarenhas
Stephen Danko
David Passmore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmacueticals Inc, Desmond Mascarenhas, Stephen Danko, David Passmore filed Critical Celtrix Pharmacueticals Inc
Priority to AU42252/99A priority Critical patent/AU761630B2/en
Priority to CA002336295A priority patent/CA2336295A1/fr
Priority to DE69926627T priority patent/DE69926627T2/de
Priority to EP99926092A priority patent/EP1082427B1/fr
Priority to AT99926092T priority patent/ATE301714T1/de
Publication of WO1999063086A2 publication Critical patent/WO1999063086A2/fr
Publication of WO1999063086A3 publication Critical patent/WO1999063086A3/fr
Publication of WO1999063086B1 publication Critical patent/WO1999063086B1/fr
Publication of WO1999063086A8 publication Critical patent/WO1999063086A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte sur des variantes de la protéine 3 de liaison native du facteur de croissance insulinoïde (IGFBP-3). Ces variantes sont modifiées de façon à résister à l'hydrolyse. L'invention porte également sur des variantes d'IGFBP-3 dans lesquelles le signal de localisation nucléaire est modifié dans IGFBP-3 native. L'invention porte, de plus, sur des IGFBP-3 allongées, à terminaison amino, qui comprennent une variété d'extensions à extrémité N terminale telles que des domaines de liaison peptidiques et nucléotidiques, des éléments de liaison spécifiques tels que des domaines de liaison de ligands à partir de récepteurs ou des domaines de liaison d'antigènes à partir d'immunoglobines, des hormones peptidiques et protéiniques et des facteurs de croissance. Les IGFBP-3 à extension N-terminal peuvent présenter une résistance à l'hydrolyse ou des variantes à signal de localisation nucléaire.
PCT/US1999/012087 1998-06-01 1999-05-28 Variantes de la proteine-3 de liaison du facteur de croissance de type insulinoide WO1999063086A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU42252/99A AU761630B2 (en) 1998-06-01 1999-05-28 Insulin-like growth factor binding protein-3 variants
CA002336295A CA2336295A1 (fr) 1998-06-01 1999-05-28 Variantes de la proteine-3 de liaison du facteur de croissance de type insulinoide
DE69926627T DE69926627T2 (de) 1998-06-01 1999-05-28 Insulinartigen wachstumsfaktor bindendes protein -3 variante
EP99926092A EP1082427B1 (fr) 1998-06-01 1999-05-28 Variantes de la proteine-3 de liaison du facteur de croissance de type insulinoide
AT99926092T ATE301714T1 (de) 1998-06-01 1999-05-28 Insulinartigen wachstumsfaktor bindendes protein -3 variante

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8755998P 1998-06-01 1998-06-01
US60/087,559 1998-06-01
US09/322,484 US6417330B1 (en) 1998-06-01 1999-05-27 Insulin-like growth factor binding protein variants
US09/322,484 1999-05-27

Publications (4)

Publication Number Publication Date
WO1999063086A2 WO1999063086A2 (fr) 1999-12-09
WO1999063086A3 true WO1999063086A3 (fr) 2000-01-27
WO1999063086B1 WO1999063086B1 (fr) 2000-04-20
WO1999063086A8 WO1999063086A8 (fr) 2000-08-10

Family

ID=26777116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012087 WO1999063086A2 (fr) 1998-06-01 1999-05-28 Variantes de la proteine-3 de liaison du facteur de croissance de type insulinoide

Country Status (9)

Country Link
US (2) US6417330B1 (fr)
EP (1) EP1082427B1 (fr)
CN (1) CN1311819A (fr)
AT (1) ATE301714T1 (fr)
AU (1) AU761630B2 (fr)
CA (1) CA2336295A1 (fr)
DE (1) DE69926627T2 (fr)
ES (1) ES2246088T3 (fr)
WO (1) WO1999063086A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109030B2 (en) * 2000-03-31 2006-09-19 Nuvelo, Inc. Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
AU2001291090B2 (en) 2000-09-19 2007-05-10 Bioexpertise, Llc Method for use of IGF-binding protein for selective sensitization of target cells in vivo
US20050033035A1 (en) * 2001-06-07 2005-02-10 Hans-Georg Beisel Mutants of igf binding proteins and methods of production of antagonists thereof
EP1435986B1 (fr) * 2001-09-18 2008-01-02 Bioexpertise, Llc Peptide derive de proteines de liaison de l'igf
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
US20050244422A1 (en) * 2004-04-16 2005-11-03 Desmond Mascarenhas Methods for delivering MBD peptide-linked agent into cells under conditions of cellular stress
WO2005049648A2 (fr) * 2003-07-09 2005-06-02 The University Of Iowa Research Foundation Proteines de liaison utilisees en chimiotherapie
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
CA2541015A1 (fr) * 2003-10-03 2005-04-14 Genentech, Inc. Proteines de liaison a l'igf
JP2008525456A (ja) * 2004-12-24 2008-07-17 インスメッド，インコーポレイテッド 精製ｒｈＩＧＦ−Ｉ／ｒｈＩＧＦＢＰ−３複合体およびその製造法
CA2633956C (fr) * 2005-12-13 2016-12-06 Olivia Raeber Proteines de liaison specifiques des facteurs de croissance analogues a l'insuline et utilisations de celles-ci
CN101495141B (zh) * 2005-12-13 2015-10-07 阿斯利康(瑞典)有限公司 胰岛素样生长因子特异性结合蛋白及其用途
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
CA2825357C (fr) 2011-02-24 2018-07-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Derives de igfbp-3 et utilisations de ceux-ci
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
EP3576767A4 (fr) 2017-02-06 2020-12-02 Academia Sinica Protéines recombinées et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023040A1 (fr) * 1993-03-26 1994-10-13 Celtrix Pharmaceuticals, Inc. Methodes et systemes d'expression de l'adn pour la surexpression de proteines dans des cellules hotes
WO1995004076A1 (fr) * 1993-08-02 1995-02-09 Celtrix Pharmaceuticals, Inc. Expression de polypeptides de fusion transportes hors du cytoplasme sans sequence de tete
WO1996040722A1 (fr) * 1995-06-07 1996-12-19 Celtrix Pharmaceuticals, Inc. Expression chromosomique de genes heterologues dans des cellules bacteriennes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5200509A (en) 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5407913A (en) 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
US5643867A (en) 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
ES2144527T3 (es) 1993-08-03 2000-06-16 Celtrix Pharma Metodo para el tratamiento de disfunciones en la reproduccion.
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
JPH09507832A (ja) 1993-09-20 1997-08-12 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆｂｐ単独またはｉｇｆｂｐとｉｇｆとの複合体による免疫疾患および血液疾患の処置
JPH09509140A (ja) 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
DE69431527T2 (de) 1993-11-15 2003-06-26 Celtrix Pharma Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
SE9303784D0 (sv) 1993-11-16 1993-11-16 Kabi Pharmacia Ab Igf
EP0800530A4 (fr) 1994-07-20 1998-12-02 Celtrix Pharma Complexe igf/igfbp destines a favoriser la formation osseuse et a reguler le remodelage osseux
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023040A1 (fr) * 1993-03-26 1994-10-13 Celtrix Pharmaceuticals, Inc. Methodes et systemes d'expression de l'adn pour la surexpression de proteines dans des cellules hotes
WO1995004076A1 (fr) * 1993-08-02 1995-02-09 Celtrix Pharmaceuticals, Inc. Expression de polypeptides de fusion transportes hors du cytoplasme sans sequence de tete
WO1996040722A1 (fr) * 1995-06-07 1996-12-19 Celtrix Pharmaceuticals, Inc. Expression chromosomique de genes heterologues dans des cellules bacteriennes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
C.A. CONOVER ET AL: "Cleavage analysis of insulin-like-growth factor (IGF)-dependent IGF-binding protein-4 proteolysis and expression of protease-resistant IGF-binding protein-4 mutants", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 270, no. 9, 3 March 1995 (1995-03-03), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., US, pages 4395 - 4400, XP002122787, ISSN: 0021-9258 *
G. JAQUES ET AL: "Nuclear localization of Insulin-like growth factor binding protein in a lung cancer cell line", ENDOCRINOLOGY, vol. 138, no. 4, April 1997 (1997-04-01), pages 1767 - 1770, XP002122807 *
R.C. BAXTER ET AL: "Modulation of human IGF binding protein-3 activity by structural modification", PROGRESS IN GROWTH FACTOR RESEARCH, vol. 6, no. 2-4, 1995, pages 215 - 222, XP002122789 *
R.T. RADULESCU: "Nuclear localization signal in insulin-like growth factor-binding protein type 3", TRENDS IN BIOCHEMICAL SCIENCES, vol. 19, no. 7, July 1994 (1994-07-01), pages 278, XP002122788 *
S.M. FIRTH ET AL: "The role of glycosylation in the action of IGFBP-3", PROGRESS IN GROWTH FACTOR RESEARCH, vol. 6, no. 2-4, 1995, pages 223 - 229, XP002122806 *
SUE M. FIRTH ET AL: "Structural determinants of Ligand and cell surface binding of Insulin-like growth Factor-Binding Protein-3", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 273, no. 5, 30 January 1998 (1998-01-30), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., US, pages 2631 - 2638, XP002122786, ISSN: 0021-9258 *
W.C. HOECK ET AL: "Identification of the major sites of phosphorylation in IGF Binding Protein-3", JOURNAL OF CELLULAR BIOCHEMISTRY., vol. 56, no. 2, October 1994 (1994-10-01), WILEY-LISS INC., US, pages 262 - 273, XP002122790, ISSN: 0730-2312 *

Also Published As

Publication number Publication date
EP1082427B1 (fr) 2005-08-10
DE69926627D1 (de) 2005-09-15
ATE301714T1 (de) 2005-08-15
AU761630B2 (en) 2003-06-05
ES2246088T3 (es) 2006-02-01
WO1999063086A2 (fr) 1999-12-09
EP1082427A2 (fr) 2001-03-14
CA2336295A1 (fr) 1999-12-09
CN1311819A (zh) 2001-09-05
US6417330B1 (en) 2002-07-09
US20020072589A1 (en) 2002-06-13
AU4225299A (en) 1999-12-20
WO1999063086B1 (fr) 2000-04-20
DE69926627T2 (de) 2006-05-24
WO1999063086A8 (fr) 2000-08-10

Similar Documents

Publication Publication Date Title
WO1999063086A3 (fr) Variantes de la proteine-3 de liaison du facteur de croissance de type insulinoide
CA2189657A1 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
WO1998055508A3 (fr) Proteines humaines ayant des domaines transmembranaires et adn codant ces proteines
ZA9810679B (en) Antimicrobial peptides.
GB9720054D0 (en) Biological products
WO1998004702A3 (fr) Proteines, notamment proteines membranaires, d'helicobacter pylori, leur preparation et utilisation
CA2249180A1 (fr) Procedes de production microbienne recombinante de proteines de fusion bpi et de peptides derives de bpi
AU4415796A (en) Production of c-terminal amidated peptides from recombinant protein constructs
EP0733071A4 (fr) Antagonistes de la chaperonine 10
EP1006126A3 (fr) Peptide possedant une activité ostéogénique
EP0161007A3 (fr) Analogues de l'hexapeptide rétro-inverso C-terminal de la substance P
CA2133834A1 (fr) Mode de preparation de proteines modifiees
WO1995030001A3 (fr) Nouvelle proteine ligand de p-selectine
AU5508396A (en) Pcna binding substance
AU3711597A (en) A novel galanin receptor
WO2000018909A3 (fr) Acides nucleiques et proteines provenant de cenarchaeum symbiosum
EP0933427A3 (fr) Gene de beta-carotenehydroxylase
WO1994029447A3 (fr) Adn codant le recepteur humain de l'hormone liberant la thyrotrophine
WO1999002708A8 (fr) Proteines de fusion comprenant des structures bispiralees derivees de la proteine inhibitrice de if1 atpase bovine
WO2001034653A3 (fr) Proteine presente a la surface des cellules souches hematopoietiques de la lignee lymphoide et des cellules nk, et ses applications.
PT1847607E (pt) Anticorpos contra a proteína p51
AU3651997A (en) Constructs and complexes of cyclin e
WO1999043834A3 (fr) Proteine constituant un ligand de la p-selectine et proteines de fusion tetrameriques
WO1998018823A8 (fr) PEPTIDES INHIBANT UNE ICE (ENZYME DE CONVERSION DE L'INTERLEUKINE-1β)
EP0959895A4 (fr) Peptides sensibles a des anticorps diriges contre un peptide consensus des proteines de la famille c54-cfa/i

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809258.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 49/99 UNDER (30) REPLACE "NOT FURNISHED" BY "09/322484"

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B8

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B8

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 49/99 UNDER (30) REPLACE "NOT FURNISHED" BY "09/322484"

WWE Wipo information: entry into national phase

Ref document number: 42252/99

Country of ref document: AU

Ref document number: 1999926092

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2336295

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1999926092

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 42252/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999926092

Country of ref document: EP